Skip to main content
Premium Trial:

Request an Annual Quote

Celera Finds Foothold in Japan


A little flattery never hurt, right? Perhaps that’s why Craig Venter, eager to expand Celera’s horizons, says Japan will play an increasingly significant role in what he calls the “golden age of discovery” in proteomics, disease prevention, and medical treatment.

“[Japan] could end up leading the world in terms of the implementation of new ideas in medicine,” Venter says. “We think some of the leading science in genomics is now beginning to take place in Japan. And Celera is very interested in helping to participate in that science.”

Celera demonstrated its commitment to the country by announcing a deal to acquire a minority interest in emerging Japanese firm HuBit Genomix, which focuses on the discovery and association of genes and SNPs for use in therapeutics and diagnostics. The size of the deal was not disclosed.

Japanese representatives at a life science symposium indicated their willingness to consider potential collaborations.

— Sara Harris


The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.